Customization of glucose targets in hybrid closed-loop (HCL) systems is important to enable tailored glucose management and safe onboarding across a wide range of users. The safety and performance of the Omnipod HCL personalized model predictive control (MPC) algorithm were assessed with a lower target of 110mg/dL for the first time in those aged 12-85y with type 1 diabetes (T1D) and A1C<10.0% using an investigational device.

A 96-h HCL study was conducted in a supervised free-living hotel setting with challenges including 2 missed meal boluses, high fat dinner, and daily exercise. All participants used a 120mg/dL target for 48h, with either a day/night target of 150/110 mg/dL (n=10) or a constant 110mg/dL target (n=10) for the remaining 48h.

Participants (n=20) were (mean±SD): age 17.9±4.4y, T1D duration 9.0±5.4y, and A1C 7.6±0.9%. Despite 2 missed meal boluses (23-162g CHO), percent time from 70-180mg/dL was 76.1±14.9% and 72.9±9.2% with targets of 110 and 120mg/dL respectively (Table). Percent time <70mg/dL was low: 2.3±2.1% and 1.9±2.5% at the respective targets.

The Omnipod personalized MPC algorithm performed well and was safe in adults and adolescents with T1D when tested at a target of 110mg/dL, even when stress-tested under challenging conditions. This algorithm is being evaluated in an at-home pivotal study with targets 110-150mg/dL.

Disclosure

G.P. Forlenza: Advisory Panel; Self; Medtronic. Consultant; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. Research Support; Self; Abbott, Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. B.A. Buckingham: Advisory Panel; Self; ConvaTec Inc., Medtronic. Research Support; Self; Beta Bionics, Inc., Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. J. Sherr: Advisory Panel; Self; Bigfoot Biomedical, Cecelia Health. Consultant; Self; Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Medtronic, Sanofi, T1D Exchange. R. Wadwa: Advisory Panel; Self; Eli Lilly and Company, Medtronic. Research Support; Self; Dexcom, Inc., Eli Lilly and Company, MannKind Corporation, Medtronic, Novo Nordisk Inc., Tandem Diabetes Care. A. Galderisi: None. L. Ekhlaspour: None. C. Berget: None. L. Hsu: Stock/Shareholder; Self; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. M. Zgorski: None. J. Lee: Employee; Self; Insulet Corporation. J.B. OConnor: None. B. Dumais: Employee; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation. Stock/Shareholder; Self; Insulet Corporation. L.M. Huyett: Employee; Self; Insulet Corporation. T.T. Ly: Employee; Self; Insulet Corporation.

Funding

Insulet Corporation

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.